Humana · Daa Pangenotypic Epclusa · US health-plan appeal rights

Daa Pangenotypic Epclusa denied for failing step therapy by Humana?

Q: How long do I have to appeal a Humana Daa Pangenotypic Epclusa denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Drug List / Part D Formulary; Humana Medical Coverage Policy Hepatitis C

The Humana angle on Daa Pangenotypic Epclusa

## Why Humana Issued a Step-Therapy Denial for Epclusa

Epclusa (sofosbuvir/velpatasvir) is a pangenotypic direct-acting antiviral. Humana's step-therapy (also called "fail-first") protocol for hepatitis C may require that a patient first try a formulary-preferred DAA before Epclusa is approved — even though both agents treat the same condition. The denial signals that Humana's records do not show a prior adequate trial of the preferred alternative, or that the required documentation of that trial was not included in the original authorization request.

Step-therapy denials are among the most frequently overturned on appeal when the patient either (a) has already tried the required step-one agent, or (b) has a documented clinical reason — such as genotype, resistance profile, or a clinical contraindication described in the prescribing label — why the step-one agent is not appropriate.

Many states have enacted step-therapy override laws requiring insurers to grant exceptions promptly when clinical criteria are met; confirm whether your state's law applies to your plan type.

## Federal Appeal Framework

ACA Section 2719 / external review: Non-grandfathered plans must offer independent external review after internal appeals are exhausted. The standard window is approximately four months from denial; urgent cases may qualify for expedited review in roughly 72 hours. Verify the exact deadline on your Explanation of Benefits.
ERISA Section 503: Employer-sponsored plans must provide a full-and-fair review and written disclosure of the step-therapy criteria.
State step-therapy override laws: If your plan is subject to state insurance regulation (typically individual or small-group, not self-funded ERISA plans), check whether your state requires an exception when a prescriber certifies the step-one drug is contraindicated or clinically inappropriate.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter and Humana's published step-therapy protocol for hepatitis C DAAs — identify which agent is required first. 2. Determine whether the patient has already tried the required agent (document dates and outcomes) or whether a clinical reason for bypassing it exists. 3. File a Level 1 internal appeal or step-therapy exception request within the plan-stated deadline, with prescriber documentation attached. 4. If upheld, escalate to external review before the deadline on the denial notice.

## Documentation to Gather

Prior DAA trial documentation: Pharmacy records, clinical notes, and lab results (viral load response) for any prior hepatitis C treatment, establishing dates and outcomes.
Reason for step-therapy bypass (if no prior trial): Prescriber documentation citing the patient's genotype, resistance-associated substitutions, or a clinical factor described in the Epclusa prescribing label that makes the step-one agent inappropriate.
Diagnosis confirmation: Current genotype, viral load, and fibrosis/cirrhosis staging.
Prescriber medical-necessity letter: A letter from the treating provider explaining why Epclusa — not the step-one alternative — is the appropriate treatment, referencing the applicable AASLD/IDSA hepatitis C guidance and the FDA-approved prescribing information.

## Criteria-Mapping Structure

From (a) the Epclusa prescribing label and (b) Humana's published step-therapy criteria, list each requirement and provide the chart-based answer. If prior trial of the step-one drug is documented, include pharmacy records and the treating provider's assessment of response. If the step is being bypassed, quote the clinical basis from the prescribing label and the relevant professional society recommendation.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Daa Pangenotypic Epclusa

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.